MedTrace Logo

Geodon for the Treatment of Refractory Social Anxiety Disorder

NCT00215150 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2014-10-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment alone

Conditions

Interventions

DRUG

Ziprasidone

Sertraline augmentation with ziprasidone

DRUG

Sertraline

Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase

Sponsors & Collaborators

Principal Investigators

  • Wei Zhang, M.D. · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2008-12-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00215150 on ClinicalTrials.gov